When building a portfolio with a long runway for gains, identifying companies that combine real commercial traction with growth-oriented technology can be a powerful strategy. One such small-cap Canadian company stands out today: a medical-technology developer that is rapidly expanding the adoption of its incision-free treatment systems across North America and Europe.

This company focuses on advanced, image-guided therapeutic systems designed to treat diseased tissue without surgical incisions. Its flagship device uses MRI guidance paired with precision ultrasound to ablate targeted prostate tissue. This approach positions the company in a niche but rapidly growing segment of the medical device market, offering patients a less invasive option that often allows same-day discharge with minimal side effects.

Revenue momentum has been strong: in its most recent reported quarter, sales jumped sharply compared to the prior year as installations of its core system increased at hospitals and treatment centers. The firm now has dozens of devices in active clinical use, with many more in advanced stages of the sales pipeline. Recurring revenue from procedures continues to climb, and gross margins have shown meaningful improvement on rising utilization and equipment sales.

Importantly, reimbursement dynamics are shifting in the company’s favor. The primary prostate procedure secured broad billing coverage under a major public healthcare program, and commercial insurance payers are beginning to reimburse at meaningful rates in some markets. These developments significantly improve the economics for both providers and the company, making adoption more sustainable and attractive.

Beyond prostate treatments, the company is exploring broader applications of its MRI-guided thermal therapy platform, including uterine fibroids and other soft-tissue conditions. New software enhancements have shortened procedure times substantially, improving competitive positioning versus alternative therapies.

Also Read: Best long term Canadian stocks

Analysts following the business see a pathway to sharply higher revenue and free cash flow over the next several years. Based on conservative valuation multiples tied to projected cash flow, the stock could potentially deliver multiple-fold returns if the company executes on its commercialization plans.

Also Read: Stock investment Canada for beginners

For investors willing to tolerate volatility and back a clinical-stage innovator with expanding commercial traction, this medical-technology specialist presents a compelling growth opportunity over the coming three years.